Patient characteristics
| Patient characteristics (N = 11) (CLL/SLL) . | No. (range or percentage) . |
|---|---|
| Male sex, n (%) | 9 (82) |
| White race, n (%) | 8 (67) |
| Baseline CLL/SLL characteristics | |
| Age at CLL diagnosis, median (range), y | 55 (43-71) |
| CLL, n (%) | 7 (64) |
| SLL, n (%) | 4 (36) |
| Cytogenetics at CLL/SLL diagnosis | |
| Del (17p) | 4/7 |
| Del (11q) | 2/7 |
| Trisomy12 | 4/7 |
| Del (13q) | 3/7 |
| Unknown | 4 |
| Complex karyotype (≥3 abnormalities) | 3/5 |
| IGHV mutation status | |
| Unmutated | 2/2 |
| Unknown | 9 |
| Molecular characteristics of CLL/SLL | |
| TP53 mutation | 2/2 |
| NOTCH-1 mutation | 1/2 |
| Unknown | 10 |
| Received therapy for CLL/SLL before RT, n (%) | |
| Yes | 6 (55) |
| No | 5 (45) |
| Lines of prior therapy, median (range) | 1 (0-6) |
| Prior type of therapy for CLL/SLL, n (%) | |
| Chemoimmunotherapy | 6 (55) |
| BTKi | 4 (36) |
| BCL2i | 2 (18) |
| Anti-CD20 mAb | 3 (27) |
| R2 | 1 (9) |
| Baseline characteristics at RS diagnosis | |
| Age, median (range), y | 61 (53-71) |
| Cytogenetics | |
| Del (17p) | 4/7 |
| Complex karyotype (≥3 abnormalities) | 4/4 |
| Unknown | 5 |
| Molecular characteristics of RS | |
| TP53 mutation | 4/5 |
| NOTCH-1 mutation | 2/3 |
| BTK mutation | 1/2 |
| DH/TH | 0/8 |
| Double expressor (Myc/BCL-2) | 7/8 |
| Ki67 index, median (range) | 90 (50-95) |
| Clonally related RS | 2/2 |
| Received therapy for RS before RICE/BTKi, n (%) | |
| Yes | 5/11 (45) |
| No | 6/11 (55) |
| Lines of therapy, median (range) | 0 (0-3) |
| Prior type of therapy for RS, n (%) | |
| Chemoimmunotherapy | 5 (45) |
| BTKi | 2 (18) |
| BCL2i | 1 (9) |
| Allo-HSCT | 1 (9) |
| Other | 1 (9) |
| ECOG score at the initiation of RICE/BTKi, n (%) | |
| 0 | 5 (45) |
| 1 | 3 (27) |
| 3 | 3 (27) |
| Patient characteristics (N = 11) (CLL/SLL) . | No. (range or percentage) . |
|---|---|
| Male sex, n (%) | 9 (82) |
| White race, n (%) | 8 (67) |
| Baseline CLL/SLL characteristics | |
| Age at CLL diagnosis, median (range), y | 55 (43-71) |
| CLL, n (%) | 7 (64) |
| SLL, n (%) | 4 (36) |
| Cytogenetics at CLL/SLL diagnosis | |
| Del (17p) | 4/7 |
| Del (11q) | 2/7 |
| Trisomy12 | 4/7 |
| Del (13q) | 3/7 |
| Unknown | 4 |
| Complex karyotype (≥3 abnormalities) | 3/5 |
| IGHV mutation status | |
| Unmutated | 2/2 |
| Unknown | 9 |
| Molecular characteristics of CLL/SLL | |
| TP53 mutation | 2/2 |
| NOTCH-1 mutation | 1/2 |
| Unknown | 10 |
| Received therapy for CLL/SLL before RT, n (%) | |
| Yes | 6 (55) |
| No | 5 (45) |
| Lines of prior therapy, median (range) | 1 (0-6) |
| Prior type of therapy for CLL/SLL, n (%) | |
| Chemoimmunotherapy | 6 (55) |
| BTKi | 4 (36) |
| BCL2i | 2 (18) |
| Anti-CD20 mAb | 3 (27) |
| R2 | 1 (9) |
| Baseline characteristics at RS diagnosis | |
| Age, median (range), y | 61 (53-71) |
| Cytogenetics | |
| Del (17p) | 4/7 |
| Complex karyotype (≥3 abnormalities) | 4/4 |
| Unknown | 5 |
| Molecular characteristics of RS | |
| TP53 mutation | 4/5 |
| NOTCH-1 mutation | 2/3 |
| BTK mutation | 1/2 |
| DH/TH | 0/8 |
| Double expressor (Myc/BCL-2) | 7/8 |
| Ki67 index, median (range) | 90 (50-95) |
| Clonally related RS | 2/2 |
| Received therapy for RS before RICE/BTKi, n (%) | |
| Yes | 5/11 (45) |
| No | 6/11 (55) |
| Lines of therapy, median (range) | 0 (0-3) |
| Prior type of therapy for RS, n (%) | |
| Chemoimmunotherapy | 5 (45) |
| BTKi | 2 (18) |
| BCL2i | 1 (9) |
| Allo-HSCT | 1 (9) |
| Other | 1 (9) |
| ECOG score at the initiation of RICE/BTKi, n (%) | |
| 0 | 5 (45) |
| 1 | 3 (27) |
| 3 | 3 (27) |
Ki67 index represents percentage of tumor cells positive for Ki67 by immunohistochemistry.
Anti-CD20 mAb, anti-CD20 monoclonal antibody; BCL2i, BCL2 inhibitor; DH/TD, double-hit/triple-hit lymphoma; ECOG, Eastern Cooperative Oncology Group; R2, lenalidomide/rituximab; SLL, small lymphocytic lymphoma.